Figure 2:
Kaplan-Meier estimates of progression-free survival in all three LGG molecular groups (A/O/G) in relation to contrast enhancement. Out of 316 patients, 98 patients (31%) showed a contrast-enhancing tumor on their preoperative MR scans. No significant differences in PFS were observed when comparing the enhancing and non-enhancing gliomas.